Eliquis (apixaban) is one of the most effective blood thinners available, with strong clinical evidence across its three main uses: preventing strokes in people with atrial fibrillation, treating blood clots, and protecting against clots after joint replacement surgery. In the landmark ARISTOTLE trial, Eliquis reduced strokes and systemic blood clots by 21% compared to warfarin, the longtime standard of care, while also causing significantly less bleeding.
Stroke Prevention in Atrial Fibrillation
Atrial fibrillation, an irregular heart rhythm that affects millions of people, dramatically raises the risk of stroke because blood can pool and clot in the heart. Eliquis is widely prescribed to reduce that risk, and the evidence behind it is robust. In the ARISTOTLE trial of over 18,000 patients, Eliquis outperformed warfarin on both effectiveness and safety. The annual rate of strokes and systemic blood clots was lower with Eliquis regardless of how well warfarin was managed in the comparison group.
What makes Eliquis particularly notable is that it achieved better stroke prevention while simultaneously causing less bleeding. Major bleeding events occurred at an annual rate of 2.13% with Eliquis versus 3.09% with warfarin, a 31% reduction. The risk of bleeding inside the brain, the most dangerous type, dropped by 58%. This combination of better efficacy and better safety is unusual for blood thinners, where stronger clot prevention typically comes with more bleeding risk.
How Eliquis Compares to Other Newer Blood Thinners
Eliquis belongs to a class of newer oral blood thinners that also includes rivaroxaban (Xarelto), edoxaban (Savaysa), and dabigatran (Pradaxa). Among these, Eliquis has the strongest safety profile. A nationwide study of over 6,200 patients with atrial fibrillation found that rivaroxaban carried roughly double the risk of major bleeding compared to Eliquis. The two-year cumulative incidence of major bleeding was 5.5% with rivaroxaban versus 2.9% with Eliquis.
In terms of stroke prevention, the difference between the two drugs was not statistically significant. The same pattern held for heart attack and overall death rates. So while both drugs prevent strokes at similar rates, Eliquis causes fewer serious bleeding events. This bleeding advantage is a major reason many cardiologists favor Eliquis when choosing among the newer blood thinners.
Treating Blood Clots in the Legs and Lungs
Eliquis is also approved to treat deep vein thrombosis (blood clots in the legs) and pulmonary embolism (clots that travel to the lungs). In the AMPLIFY trial, it matched the effectiveness of conventional treatment (injectable blood thinners followed by warfarin) while causing less bleeding. For people who need extended treatment to prevent clots from coming back, the results are equally encouraging.
The AMPLIFY-EXT trial tested whether a low dose of Eliquis could safely prevent recurrent clots in patients who had already completed their initial treatment course. Over 12 months, both low-dose and standard-dose Eliquis significantly reduced the risk of recurrent or fatal blood clots compared to placebo. The rates of major bleeding were remarkably low: 0.2% for the lower dose and 0.1% for the higher dose, both comparable to the placebo group’s 0.5%. In longer-term follow-up studies, the recurrence rate on low-dose therapy remained around 3.7% over a median treatment period of more than two years.
Preventing Clots After Joint Replacement
Hip and knee replacement surgeries carry a significant risk of blood clots forming in the legs. Eliquis has been tested against enoxaparin, an injectable blood thinner that was the previous standard for post-surgical clot prevention, and performed well in three large trials known as ADVANCE 1, 2, and 3.
After knee replacement (ADVANCE 2), Eliquis reduced the combined risk of any blood clot or death by 38% compared to enoxaparin injections. After hip replacement (ADVANCE 3), the results were even more striking: a 64% reduction in the same combined outcome. The risk of major clots, including large deep vein clots and pulmonary embolism, was cut roughly in half in both settings. Eliquis also has the practical advantage of being a pill rather than an injection, which matters when patients are managing recovery at home.
How Quickly It Works
Eliquis starts working relatively fast. Blood levels reach their peak about 3 to 4 hours after taking a tablet, and the drug has a half-life of roughly 12 hours. This means it stays active in your system long enough to be taken twice daily but clears quickly enough that its anticoagulant effect fades within a day or two of stopping. For context, warfarin can take days to reach full effect and days to wear off. This predictable timeline simplifies planning around procedures and managing missed doses.
Who Gets a Lower Dose
Most people with atrial fibrillation take the standard 5 mg twice daily. A lower dose of 2.5 mg twice daily is used for patients who meet at least two of three criteria: age 80 or older, body weight of 132 pounds (60 kg) or less, or a specific marker of reduced kidney function (serum creatinine of 1.5 mg/dL or higher). This dose adjustment keeps the drug effective while accounting for slower clearance of the drug in these patients. For clot prevention after surgery, the standard dose is 2.5 mg twice daily for everyone.
What Happens in a Bleeding Emergency
One historical concern with newer blood thinners was the lack of a reversal agent. That changed with the approval of andexanet alfa, a medication designed to rapidly neutralize the blood-thinning effect of Eliquis and similar drugs. In a study of patients experiencing major bleeding while on these medications, andexanet alfa reduced the activity of Eliquis in the blood by 93% and achieved good or excellent bleeding control in about 79% of patients taking Eliquis specifically. Across all types of bleeding, including gastrointestinal and intracranial, the success rate was around 80%. While no reversal agent works perfectly in every situation, the availability of this option addresses one of the earlier drawbacks of choosing Eliquis over warfarin, which has long had reliable reversal methods.
Practical Advantages Over Warfarin
Beyond the clinical trial numbers, Eliquis offers several day-to-day benefits that affect quality of life. Warfarin requires regular blood tests (often every few weeks) to ensure the dose is correct, and its effectiveness varies widely depending on diet, other medications, and genetics. Many patients on warfarin spend significant stretches of time either under-protected or over-thinned. Eliquis requires no routine blood monitoring, has far fewer food and drug interactions, and delivers a more consistent level of protection from day to day.
The trade-off is cost. Eliquis remains significantly more expensive than generic warfarin, though generic versions of apixaban are beginning to reach the market, which should narrow that gap over time.